AdvisorShares Pure US Cannabis ETF

MSOS

Market cap $891M

Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism.

Video posted on Truth Social touts CBD as a ‘gamechanger' and promotes Medicaid coverage of CBD products

Cannabis stocks got a pop on Monday after President Trump shared a video highlighting potential health benefits of CBD, reigniting speculation that his administration could reclassify the drug, CNBC's Brandon Gomez reports.

President Donald Trump posted a video on Truth Social on Sunday, promoting the potential health benefits of cannabis. Cannabis stocks lit up on Monday after Trump resurrected hopes for a change in federal drug policy.

Small caps led Q3 gains, while other standout ETF areas are Bitcoin mining (WGMI, MNRS), cannabis (MSOS, WEED), Ethereum (ETH, ETHW) and rare earths (REMX).

Cannabis has bipartisan support, but is it worthy of your investment? Quant Strategist Emma Johnston on how quant thinks about sector ETF MSOS, currently rated a buy due to strong momentum and liquidity, with high regulatory risk.

Optimism that the Trump administration will soon reschedule cannabis, thereby removing the Section 280E tax burden and boosting sector profitability, has fueled a dramatic rally in cannabis stocks. MSOS ETF saw a 27.2% increase in shares outstanding and inflows of about $165 million since July, reflecting surging investor interest in U.S. cannabis stocks. MSOS aggressively increased positions in key cannabis companies, with notable additions and significant percentage increases in holdings across its portfolio.

Investors are closely watching the US cannabis space after President Donald Trump signaled plans to reschedule marijuana, a move that is expected to unlock near-term financial relief and longer-term growth for the industry. Trump recently stated that his administration will “be moving forward soon with rescheduling marijuana,” referring to its reclassification as a lower-risk Schedule III drug.

Cannabis ETF spent the first half of the year in the performance doldrums. But they have rallied of late on news that the Trump administration is open to reclassifying marijuana as a less dangerous drug.